We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
TRANSFUSION IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA.
- Authors
Samaras, Athena T.; Bennett, Charles L.; Lai, Stephen Y.
- Abstract
Recent studies questioning the safety of erythropoiesis-stimulating agent (ESA) therapy and the resultant cautionary US Food and Drug Administration statements and Medicare reimbursement restrictions have impacted transfusion utilization patterns, both in the United States and internationally. This article explores various utilization studies (in Europe, Canada, and in the United States) relating to the complex relationship between ESA regulatory and reimbursement actions, patterns of ESA use, and transfusion practices. In general, ESAs are used more frequently in the United States than in Europe, where the approach has been to administer ESAs or to transfuse red blood cells to patients with chemotherapy-induced anemia (CIA) who were symptomatic, rather than to those who would potentially require a transfusion in the future. However, the European Medicines Agency does note concerns regarding blood transfusions, with the limited supply of blood in Europe being the major issue. Also included in this article, are general trends in CIA management (both in Europe and in the United States) and factors to consider in identifying patients with CIA at risk for blood transfusion.
- Subjects
UNITED States; ERYTHROPOIESIS; BLOOD transfusion; UNITED States. Food &; Drug Administration; MEDICARE; DRUG therapy
- Publication
Johns Hopkins Advanced Studies in Medicine, 2008, Vol 8, Issue 10, p352
- ISSN
1530-3004
- Publication type
Article